Last updated: 2026-09-08 07:52:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Pulmatrix, Inc. (PULM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.36, with a market capitalization of $5.08M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.16 to $5.50. This page covers its latest market performance, valuation, price trends and company information.
$5.08M | |
$1.36 | |
$2,910.00 | |
$1.16 | |
$1.36 | |
19.76K | |
47.11K | |
-- | |
$5.50 | |
$1.16 | |
-- | |
-- |
Pulmatrix, Inc. (PULM) last closed at $1.36 as of 2026-09-04 23:57:00, unchanged from the previous close of $1.36.
During the latest regular trading session, PULM traded between $1.16 and $2,910.00, with a volume of 19.76K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Pulmatrix, Inc. (PULM) moved from $1.52 to $1.36, representing a decline of 10.53% ($0.16).
The stock traded between $1.36 and $1.60 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 11.40 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 4.6%
PULM is currently trading at $1.36, placing it 4.6% of the way from its 52-week low of $1.16 to its 52-week high of $5.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Pulmatrix, Inc. (PULM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.